Evidence map›Paper›PMID 38667695›Full record

ArticleGels (Basel, Switzerland)2024

Comprehensive Evaluation of Injectability Attributes in OxiFree™ Dermal Fillers: MaiLi

Patrick Micheels, Alexandre Porcello, Thierry Bezzola, Daniel Perrenoud, Marie-Odile Christen, Lee Ann Applegate, Alexis Laurent

Abstract read
In one paragraph

Article in Gels (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Patrick MicheelsPrivate Medical Practice, CH-1224 Chêne-Bougeries, Switzerland.
Alexandre PorcelloDevelopment Department, Abcello Sàrl, CH-1432 Belmont-sur-Yverdon, Switzerland.ORCID 0000-0003-1603-2704
Thierry BezzolaPrivate Medical Practice, CH-1204 Geneva, Switzerland.
Daniel PerrenoudPrivate Medical Practice, CH-1006 Lausanne, Switzerland.
Marie-Odile ChristenPrivate Office, F-75116 Paris, France.
Lee Ann ApplegateRegenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Epalinges, Switzerland.ORCID 0000-0002-7346-9921
Alexis LaurentRegenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Epalinges, Switzerland.ORCID 0000-0001-5738-8702

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dermal filler injectability is a critical factor for commercial product adoption by medical aesthetic professionals and for successful clinical administration. We have previously reported (in vitro and ex vivo) cross-linked hyaluronic acid (HA)-based dermal filler benchmarking in terms of manual and automated injectability requirements. To further enhance the function-oriented product characterization workflows and the clinical relevance of dermal filler injectability assessments, the aim of this study was to perform in vivo evaluations. Therefore, several variants of the MaiLi

Indexed as

aesthetic medicinecase reportscross-linked hyaluronic aciddermal fillershydrogel systemsinjectabilitymedical deviceneedle gaugeOxiFree™ technologytechnical benchmarking

Identifiers

PMID38667695
PMCPMC11049332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.